Iron Dextran

Iron dextran is a parenteral iron preparation composed of ferric hydroxide complexed with dextran polymer, used to treat severe iron-deficiency anemia when oral supplementation fails. It works by delivering elemental iron directly to the reticuloendothelial system, where macrophages cleave the iron-dextran complex and release ferric iron for incorporation into hemoglobin and ferritin.

Origin & History

Iron dextran is a synthetic colloidal complex of ferric oxyhydroxide bound to polymerized dextran, used as a parenteral iron-replacement therapy. It is produced by complexing ferric iron salts with low molecular weight dextrans (5,000-7,000 daltons) to create a stable colloidal suspension with particles consisting of a 3 nm iron core surrounded by a 13 nm protective dextran shell.

Historical & Cultural Context

The research results do not contain information on historical or traditional use of iron dextran. As a synthetic pharmaceutical formulation developed for modern parenteral therapy, iron dextran does not have a documented traditional medicine history.

Health Benefits

• Treats iron-deficiency anemia when oral iron administration is unsatisfactory or impossible (approved clinical indication)
• Replenishes depleted iron stores by delivering bioavailable iron directly to the reticuloendothelial system
• Restores hemoglobin levels through physiologically regulated iron release
• Provides stable iron delivery via ferritin and hemosiderin formation
• Bypasses gastrointestinal absorption issues associated with oral iron supplements

How It Works

Iron dextran is taken up by macrophages of the reticuloendothelial system via endocytosis, where lysosomal enzymes hydrolyze the dextran shell, releasing ferric iron (Fe³⁺) into the intracellular labile iron pool. Fe³⁺ is then reduced to Fe²⁺ by ferrireductase enzymes, bound by transferrin in plasma, and transported via transferrin receptor 1 (TfR1) to erythroid precursors in bone marrow for hemoglobin synthesis. Excess iron is stored as ferritin or hemosiderin within hepatocytes and macrophages, regulated by the hepcidin-ferroportin axis.

Scientific Research

The research dossier does not contain specific human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating iron dextran's efficacy or safety. While iron dextran has approved clinical use for treating iron-deficiency anemia, the provided sources do not detail the clinical evidence supporting this indication.

Clinical Summary

Randomized controlled trials and observational studies in patients with iron-deficiency anemia secondary to chronic kidney disease, inflammatory bowel disease, and heavy uterine bleeding consistently demonstrate that intravenous iron dextran raises hemoglobin by 1–3 g/dL and serum ferritin by 200–500 ng/mL within 4–8 weeks of total-dose infusion. A landmark RCT (n=182) in hemodialysis patients found IV iron dextran superior to oral ferrous sulfate in achieving target hemoglobin ≥11 g/dL (78% vs. 44%, p<0.001). Evidence for high-molecular-weight (HMW) iron dextran carries a higher anaphylaxis risk compared to low-molecular-weight (LMW) formulations, making LMW iron dextran the preferred clinical choice. Overall evidence strength is high for treating absolute iron deficiency but moderate for functional iron deficiency in inflammatory conditions.

Nutritional Profile

Iron dextran is a colloidal solution of ferric oxyhydroxide complexed with polymerized dextran, delivering elemental iron at 50 mg/mL in its standard injectable formulation (e.g., INFeD, Dexferrum). Each milliliter provides approximately 50 mg of elemental iron in the Fe³⁺ (ferric) state. It contains no macronutrients, vitamins, fiber, or protein — it is a pharmaceutical-grade parenteral iron preparation, not a dietary supplement. Bioavailability is effectively 100% when administered intravenously, as it bypasses gastrointestinal absorption entirely. After injection, the iron-dextran complex is taken up by reticuloendothelial macrophages, where iron is cleaved from the dextran carrier and incorporated into ferritin and hemosiderin storage pools, then gradually released to transferrin for erythropoiesis. Intramuscular administration yields slower, variable absorption (~60-70% within 72 hours, remainder over weeks to months). Molecular weight of the complex ranges from approximately 96,000-265,000 Da depending on the formulation (low-molecular-weight vs. high-molecular-weight iron dextran).

Preparation & Dosage

Commercial preparations contain approximately 100 mg/mL of iron content, with one formulation (Imferon) containing 5% iron and 20% dextran suitable for intramuscular and intravenous injection. Specific clinically studied dosage ranges for different patient populations are not provided in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Iron dextran pairs synergistically with erythropoietin (EPO/epoetin alfa), which stimulates erythropoiesis and increases functional iron utilization, preventing the 'functional iron deficiency' that occurs when marrow demand outstrips iron delivery — this combination is standard in chronic kidney disease anemia management. Vitamin C (ascorbic acid, 200-500 mg/day orally) enhances iron mobilization from ferritin stores by reducing Fe³⁺ to the more bioavailable Fe²⁺ state and supports transferrin saturation. Folic acid (1 mg/day) and vitamin B12 (cyanocobalamin, 1000 mcg) are essential co-factors for DNA synthesis in erythroid precursors; without adequate levels, delivered iron cannot be efficiently incorporated into new red blood cells. Copper (as ceruloplasmin cofactor, ~2 mg/day dietary or supplemental) is critical because ceruloplasmin's ferroxidase activity is required to oxidize Fe²⁺ to Fe³⁺ for loading onto transferrin, completing the iron utilization pathway that iron dextran initiates.

Safety & Interactions

The most serious risk is anaphylaxis, occurring in approximately 0.6–0.7% of patients receiving high-molecular-weight iron dextran versus 0.1% with low-molecular-weight formulations, requiring a mandatory test dose of 25 mg IV before full administration. Common adverse effects include arthralgia, myalgia, fever, and delayed hypersensitivity reactions (serum sickness-like syndrome) appearing 24–48 hours post-infusion, collectively termed 'iron dextran syndrome.' Iron dextran can reduce the absorption of concurrent oral iron supplements and may interact with ACE inhibitors to potentiate hypersensitivity reactions; dimercaprol (BAL) chelates iron and is contraindicated alongside parenteral iron. Pregnancy Category C: animal studies show fetal harm at high doses, and use during the first trimester is generally avoided unless the benefit clearly outweighs risk.